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Abstract 
 
Background 
Small bowel obstruction (SBO) is a condition which is commonly treated by general surgeons. The 
evidence base for treatment of this condition is limited in part by variable reporting of outcomes in 
the literature. The aim of this study was to identify commonly used outcomes in research on SBO.    
Methods 
This review was reported in line with PRISMA guidelines and registered with PROSPERO 
(CRD42017065538). Searches were performed of MEDLINE, EMBASE and CENTRAL databases to 
identify prospective cohort or randomised trials reporting outcomes of interventions in SBO. Studies 
addressing diagnostics, paediatric populations, and SBO due to malignancy were excluded. Studies 
were screened for inclusion. Study and outcome characteristics were extracted into a predesigned 
proforma and mapped onto the OMERACT framework.  
Results 
A total of 1,222 studies were screened for eligibility, 74 full text articles retrieved and 51 studies 
included for synthesis. A total of 50 different outcomes were used. Duration of hospital stay was the 
most frequently reported outcome (n=21 studies). Resolution of SBO was reported in 12 studies, but 
only defined in 8 studies which used 6 different definitions. Patient reported outcomes were 
reported in only four studies.   
Discussion 
There is a high degree of variation in the outcomes reported in SBO research. There is a clear need 
for a core outcome set. Development of a patient reported outcome measure for this condition 
should also be explored. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Background 
 
Small bowel obstruction is a common condition, accounting for around half of all emergency 
laparotomies each year1. Outcomes for this condition are poor, with high rates of morbidity and 
mortality reported1 2. As this is a high volume condition with poor outcomes, it is important to 
improve the care of patients with small bowel obstruction, through quality improvement and 
research3 4. 
It is well recognised that surgery lacks the high-quality evidence in the form of randomised 
controlled trials seen in other clinical fields5. One of the challenges to research both in trials and 
cohort studies is selective reporting bias, which limits comparison of studies and has potential to 
skew reporting of key benefits and harms of treatments6 7. In order to address this, it is important to 
have a common set of outcomes with matching definitions. This could be achieved through the 
ĚĞǀĞůŽƉŵĞŶƚ ‘ŽƌĞKƵƚĐŽŵĞ^Ğƚ ? ?K^ ? ? defined aƐ ‘ĂŶĂŐƌĞĞĚ ?ƐƚĂŶĚĂƌĚŝƐĞĚƐĞƚŽĨŽƉƚŝŵĂůŽƵƚĐŽŵĞ
measures that should be reported, as a minimum, in all studies investigating a specific clinical 
ƉŽƉƵůĂƚŝŽŶ ?8. In 2010, the Core Outcome Measures in Effectiveness Trials (COMET) initiative 
(http://www.comet-initiative.org/) was launched with the aim of addressing the problem of a lack of 
outcome measurement standardisation in clinical trials9. Core outcome sets have already been 
produced in other surgical conditions10 11. The first step in the production of a COS is to identify 
commonly used outcomes in the literature. Qualitative work is undertaken with patients to identify 
additional outcomes of importance. The long list is then presented to stakeholders including 
clinicians and patients and a consensus process (e.g. Delphi) is followed to reach a consensus on 
which are most important12. 
The aim of this study was to identify and categorise outcomes used in research on small bowel 
obstruction.  
 
Method 
 
A protocol for this systematic review is available on PROSPERO (registration: CRD42017065538). The 
review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines13. 
 
Search strategy 
A search strategy was devised with input from a librarian at the School of Health and Related 
Research, University of Sheffield. Electronic databases searched included: MEDLINE (accessed 
through the PubMed interface), EMBASE (accessed through the OVID interface), and the Cochrane 
Central Register of Controlled Trials (CENTRAL). Validated filters were used to search for RCTs in 
EMBASE, and MEDLINE14 15. The search strategy is presented in appendix 1. Backwards citation 
tracking of reference lists of relevant reviews, and forwards citation tracking of relevant articles, 
were also used, as per COMET guidance16. Further hand searching of all titles and relevant abstracts 
ŽĨƐƚƵĚŝĞƐƉƵďůŝƐŚĞĚŝŶƚŚĞ ‘ƌŝƚŝƐŚ:ŽƵƌŶĂůŽĨ^ƵƌŐĞƌǇ ? ?ĂŶĚ ‘ŶŶĂůƐŽĨ^ƵƌŐĞƌǇ ?ǁĞƌĞƵƐĞĚƚŽŝĚĞŶƚŝĨǇ
relevant publications within the last 20 years. 
 
Eligibility criteria 
All randomised controlled trials (RCTs) and prospective cohort studies were included. No restriction 
was placed on publication date. Only English language articles were included due to time and 
resource constraints. The target population was adults with SBO, irrespective of duration of disease. 
Studies evaluating the clinical effectiveness of any therapeutic intervention for SBO were eligible. No 
restriction was placed on comparator interventions. Any construct used to evaluate the clinical 
effectiveness of therapeutic interventions for SBO were eligible. 
Manuscripts which were retrospective, conference abstracts of study protocols were excluded. 
Studies addressing diagnosis of SBO or treatment in paediatric populations were excluded. Reports 
of SBO due to peritoneal carcinomatosis, left sided colonic tumour, or immediately following other 
procedures, were also excluded as cancer related outcomes are less applicable to the general SBO 
population. 
 
Study selection 
Literature search results were exported and de-duplicated manually by comparing multiple data 
from each publication. One researcher considered the title and abstract of each study identified, and 
obtained the full texts of studies included at this stage. When full texts could not be accessed 
through the University of Sheffield resources, or by request to the author, they were requested 
through the British library. One researcher analysed the full texts of each study to identify those for 
inclusion. Guidance from the research team was sought regarding eligibility queries. 
Data extraction and analysis 
Data on publication details, study design and characteristics, intervention/comparator details, 
outcome measures and definitions were extracted into a pre-designed pro forma. 
Outcome data were extracted as reported, and tables were constructed to indicate reported or 
omitted ŽƵƚĐŽŵĞƐ ? ŽŵƉŽƐŝƚĞ ŽƵƚĐŽŵĞƐ ? Žƌ ƵŵďƌĞůůĂ ƚĞƌŵƐ ? ƐƵĐŚ ĂƐ ‘ĐŽŵƉůŝĐĂƚŝŽŶƐ ? ? ǁĞƌĞ
decomposed into their component constructs. Outcomes were subsequently categorised into 
domains based on the OMERACT Filter 2.0 framework17. OMERACT is a framework for selecting and 
measuring outcomes when deciding which outcomes to include in a COS. OMERACT specifies four 
core areas (death, life/impact, resource use/economic impact, and pathophysiological 
manifestations) which are recommended to be considered and measured to assess the overall effect 
of an intervention on a specific health condition. 
In keeping with similar reviews where list of outcomes reported are collated and not synthesised18 19, 
neither bias or quality assessment or meta-analysis of included studies was planned. 
 Results 
 
Search 
Electronic database searches retrieved 1,467 results. 31 additional results were obtained through 
other sources: 5 through citation tracking, 14 through screening reference lists, and 12 through hand 
searching of key journals (5 from the British Journal of Surgery, and 7 from the Annals of Surgery). 
After de-duplication 1,222 results remained to be screened; 74 full texts were retrieved and 23 were 
excluded, leaving 51 studies were included in the final review (Figure 1). 
Included studies were published between the years of 1988  ? 2015. Twenty studies focussed on 
operative management of SBO (3 RCTs20 21 22, and 17 prospective cohort studies2 23-38 ) 31 focussed 
on conservative management (21 RCTs39-59, and 10 prospective cohort studies60-68). Study 
characteristics presented in supplementary file 1. 
A range of 50 different outcome measures were reported within the 51 included studies. These 
outcomes were then categorised into 9 separate domains and mapped to core areas based on the 
OMERACT Filter 2.0, displayed in Table 1. 
Synthesis of results 
Application of the OMERACT Filter to outcomes found areas of overlap where outcomes could be 
categorised in multiple domains. For example, outcomes associated with pain, specifically pain 
scores as assessed using a scale, could be interpreted either as a patient reported outcome (PRO; 
ĐŽƌĞ ĂƌĞĂ  ‘ůŝĨĞ ŝŵƉĂĐƚ ? ? ? Žƌ ĂƐ ĂŶ ĂŶĂůŐĞƐŝĐ ŵĞĂƐƵƌĞ  ?ĐŽƌĞ ĂƌĞĂ ŽĨ  ‘ƉĂƚŚŽƉŚǇƐŝŽůŽŐŝĐĂů
ŵĂŶŝĨĞƐƚĂƚŝŽŶƐ ? ? ?ƐĞĞ&ŝŐƵƌĞ ? ? 
 
Pathophysiological manifestations 
The pathophysiological manifestation core area encompassed three sub-ĚŽŵĂŝŶƐ P  ‘'ĞŶĞƌĂů
ƉƌŽĐĞĚƵƌĂů ŵĞĂƐƵƌĞƐ ? ?  ‘ƉƌŽĐĞĚƵƌĞ ƐƉĞĐŝĨŝĐ ŵĞĂƐƵƌĞƐ ? ĂŶĚ  ‘ĂŶĂůŐĞƐŝĐ ŵĞĂƐƵƌĞƐ ? ?to which 17 
outcomes were assigned. General procedural measures included outcomes applicable to most 
ƚŚĞƌĂƉĞƵƚŝĐŝŶƚĞƌǀĞŶƚŝŽŶƐŝŶĐůƵĚŝŶŐƚŚĞ ‘ĚƵƌĂƚŝŽŶŽĨŚŽƐƉŝƚĂůƐƚĂǇ ?ĂŶĚ ‘ƚŝŵĞƚŽƌĞƐŽůƵƚŝŽŶ ? ?dŚĞƚĞƌŵ
 ‘ƌĞƐŽůƵƚŝŽŶ ? ǁĂƐ ƌĞƉŽƌƚĞĚ ŝn 12 studies, and defined in 8 (Table 2). There was significant 
ŚĞƚĞƌŽŐĞŶĞŝƚǇ ƐƵƌƌŽƵŶĚŝŶŐ ƚŚĞ ĚĞĨŝŶŝƚŝŽŶ ? ĂŶĚ ƚŚĞ ŽƵƚĐŽŵĞ ĐĂŶ ďĞ ĚĞƐĐƌŝďĞĚ ĂƐ Ă  ‘ĐŽŵƉŽƵŶĚ
ŽƵƚĐŽŵĞ ? ?ĨŽƌǁŚŝĐŚĚŝĨĨĞƌĞŶƚĂƵƚŚŽƌƐƐĞůĞĐƚĚŝĨĨĞƌĞŶƚĐŽŵƉŽŶĞŶƚƐƚŽĞŶĐŽŵƉĂƐƐƚŚĞƐĂŵĞĐŽŶĐĞƉƚ ?
with ŶŽƐƚĂŶĚĂƌĚŝƐĞĚĚĞƐĐƌŝƉƚŝŽŶ ?dŚĞŵŽƐƚĨƌĞƋƵĞŶƚůǇƵƐĞĚĚĞĨŝŶŝƚŝŽŶŽĨ ‘ƌĞƐŽůƵƚŝŽŶ ?ŝŶǀŽůǀĞĚďŽƚŚ
the absence of associated symptoms, and radiographic improvement. One study that used this 
definition recognised the absence of certain components, suggesting additional concepts such as the 
reduction in abdominal pain would improve the definition65. The sub-ĚŽŵĂŝŶ  ‘ƉƌŽĐĞĚƵƌĞ ƐƉĞĐŝĨŝĐ
ŵĞĂƐƵƌĞƐ ? ŝŶĐůƵĚĞĚ ŽƵƚĐŽŵĞ ŵĞĂƐƵƌĞƐ ƌĞƉŽƌƚĞĚ ƚŚĂƚ ǁĞƌĞ ůĂƌŐĞůǇ ĚĞƉĞŶĚĞŶƚ ŽŶ ƚŚĞ ƐƚƵĚǇ
inteƌǀĞŶƚŝŽŶ ? &Žƌ ĞǆĂŵƉůĞ ? ƐƚƵĚŝĞƐ ŽĨ ŽƉĞƌĂƚŝǀĞ ŵĂŶĂŐĞŵĞŶƚ ĐŽŵŽŶůǇ ƌĞƉŽƌƚĞĚ ƚŚĞ  ‘ĐŽŶǀĞƌƐŝŽŶ
ƌĂƚĞ ? ĨƌŽŵ ůĂƉĂƌŽƐĐŽƉǇ ƚŽ ůĂƉĂƌŽƚŽŵǇ ǁŚĞŶ ůĂƉĂƌŽƐĐŽƉǇ ǁĂƐ ƵƐĞĚ ? ĂŶĚ ƚŚĞ  ‘ƌĂƚĞ ŽĨ ďŽǁĞů
ƌĞƐĞĐƚŝŽŶƐ ? ? ŚŽǁĞǀĞƌ ŽŶůǇ ŽŶĞ ƐƚƵĚǇ ƐƉĞĐŝĨŝĞĚ ƚŚĞ ŵĞĚŝĂŶ ƌĞƐĞĐƚŝŽŶ ůĞŶŐƚŚ67. Studies looking at 
conservative management, namely water soluble contrast agents, reported outcomes such as 
 ‘ĚĞƚĞĐƚŝŽŶ ŽĨ ĐŽŶƚƌĂƐƚ ŝŶ ƚŚĞ ĐŽůŽŶ ? ĂŶĚ ƚŚĞ  ‘ƐƵŝƚĂďŝůŝƚǇ ĂŶĚ ƚŽůĞƌĂďŝůŝƚǇ ŽĨ ĐŽŶƚƌĂƐƚ ŵĞĚŝĂ ? ? KƚŚĞƌ
outcome measures were intervention specific and only reported in a few studies. The final sub-
ĚŽŵĂŝŶ ‘ĂŶĂůŐĞƐŝĐŵĞĂƐƵƌĞƐ ?ĐŽŶƚĂŝŶĞĚŽƵƚĐŽŵĞƐƌĞƉŽƌƚĞĚĂĐƌŽƐƐŽŶůǇƚǁŽƐƚƵĚŝĞƐ ? 
Resource use 
dŚĞ ƌĞƐŽƵƌĐĞ ƵƐĞ ĐŽƌĞ ĂƌĞĂ ĐŽŶƚĂŝŶƐ ƚŚĞ ĚŽŵĂŝŶ  ‘ƉƌŽĐĞƐƐ ŵĞĂƐƵƌĞƐ ? ŽŶůǇ ?to which 13 outcomes 
were assigned. The majority of these outcomes were based on the rates and successes of different 
ŝŶƚĞƌǀĞŶƚŝŽŶƐ ? ƐƵĐŚ ĂƐ  ‘ŽƉĞƌĂƚŝǀĞ ƌĂƚĞ ? ?  ‘ƚŝŵĞ ĨƌŽŵ ĂĚŵŝƐƐŝŽŶ ƚŽ ŝŶƚĞƌǀĞŶƚŝŽŶ ? ĂŶĚ  ‘intervention 
ƐƵĐĐĞƐƐ ƌĂƚĞ ?  ?ĚĞĨŝŶĞĚ ŝŶ ƚǁŽ ƐƚƵĚŝĞƐ ĂƐ ǁŚĞƚŚĞƌ ƉĂƚŝĞŶƚƐ ƌĞŵĂŝŶĞĚ  ‘ĂƐǇŵƉƚŽŵĂƚŝĐ ĂĨƚĞƌ ƚŚĞ ůĂƐƚ
follow-ƵƉ ? ?24 38.  
Life impact 
The life impact core area was the most diverse, containing 20 different outcomes. This core area was 
categorised into 5 sub-domains. The sub-ĚŽŵĂŝŶ  ‘'/ ƌĞĐŽǀĞƌǇ ? ŝŶĐůƵĚĞƐ ŽƵƚĐŽŵĞƐ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ
dietary resumption and return of bowel function (defined in 7 studies as the first bowel movement, 
and appearance of flatus and/or defecation)20 36 37 44 54 57 68 ? &ŽƵƌ ƐƚƵĚŝĞƐ ƌĞƉŽƌƚĞĚ WZKƐ ? ? ďƵƚ ŶŽ
studies reported on patient overall quality of life.  
Complications of management 
ůŝŶŝĐŝĂŶ ƌĞƉŽƌƚĞĚ ŽƵƚĐŽŵĞƐ  ?ZK ?Ɛ ? ǁĞƌĞ ĨƌĞƋƵĞŶƚůǇ ĂƐƐĞĚ ǁŝƚŚŝŶ ƚŚĞ ƐƚƵĚŝĞƐ ǁŝƚŚ  ? ? ƐƚƵĚŝĞƐ
(73%) reporting at least oŶĞ ŽĨ ƚŚĞ ŽƵƚĐŽŵĞƐ  ‘ŵŽƌƚĂůŝƚǇ ? ?  ‘ŵŽƌďŝĚŝƚǇ ? Žƌ  ‘ĐŽŵƉůŝĐĂƚŝŽŶƐ ŽĨ
ŵĂŶĂŐĞŵĞŶƚ ? ? dŚĞ ƌĂŶŐĞ ŽĨ ĐŽŵƉůŝĐĂƚŝŽŶƐ ƌĞƉŽƌƚĞĚ ǁŝƚŚŝŶ ƐƚƵĚŝĞƐ ǀĂƌŝĞĚ ? ĂŶĚ ƐŽŵĞ ƐƚƵĚŝĞƐ
ĐĂƚĞŐŽƌŝƐĞĚ ĐŽŵƉůŝĐĂƚŝŽŶƐ ŝŶƚŽ  ‘ŝŶƚƌĂŽƉĞƌĂƚŝǀĞ ? ĂŶĚ  ‘ƉŽƐƚŽƉĞƌĂƚŝǀĞ ?20 26 30 38 59 ?  ‘ĞĂƌůǇ ? ĂŶĚ  ‘ůĂƚĞ ?22; 
 ‘ŵĞĚŝĐĂů ? ĂŶĚ  ‘ƐƵƌŐŝĐĂů ?27 67; Žƌ  ‘Ăůů ? ĂŶĚ  ‘ŵĂũŽƌ ? ?36 however, most did not offer such categorical 
reporting. Most studies reported a breakdown of the varied health states that contributed to the 
complication composite outcome, seven studies did not. In total, 43 unique outcome terms 
associated with complications were identified. The most frequently reported complications were 
ŵĂƉƉĞĚ ƚŽ ĚŽŵĂŝŶƐ ŽĨ  ‘ĚŝƌĞĐƚ ƉƌŽĐĞĚƵƌĂů ? ?  ‘ƐǇƐƚĞŵŝĐ ƉŽƐƚ-ŽƉĞƌĂƚŝǀĞ ? ?  ‘ůŽĐĂů ƉŽƐƚ- ƉĞƌĂƚŝǀĞ ? ĂŶĚ 
 ‘'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂů ?'/ ?ƌĞĐŽǀĞƌǇ ? ?&igure 3 & Table 3). There was inconsistency within the reporting of 
ƚŚĞ ŽƵƚĐŽŵĞƐ  ‘ĂŶĂƐƚŽŵŽƚŝĐ ďƌĞĂŬĚŽǁŶ ? ? ĂŶĚ  ‘ƐŵĂůů ďŽǁĞů ůĞĂŬĂŐĞ ? ? ĂŶĚ  ‘ƐŵĂůů ďŽǁĞů ƌĞĐƵƌƌĞŶĐĞ ?
either as individual outcomes or as a component of the comƉŽƵŶĚŽƵƚĐŽŵĞ ‘ĐŽŵƉůŝĐĂƚŝŽŶƐ ?20 30 31 37 
45 54.  
Long-term outcomes and others 
 KƚŚĞƌ ƐƚƵĚǇ ƐƉĞĐŝĨŝĐ ZK ?Ɛ ǁĞƌĞ ĂůƐŽ ƌĞƉŽƌƚĞĚ21 44. The final sub-ĚŽŵĂŝŶ  ‘ůŽŶŐ ƚĞƌŵ ŽƵƚĐŽŵĞƐ ?
ŝŶĐůƵĚĞƐ ‘ŚŽƐƉŝƚĂůƌĞĂĚŵŝƐƐŝŽŶƌĂƚĞ ?27 36 40, and outcomes associated with SBO recurrence. 
 
Discussion 
 
This study reports the results of a systematic review and categorisation of outcomes reported in 
studies on small bowel obstruction. It is the first to attempt to classify outcomes for this condition 
using the OMERACT tool. 
In keeping with other surgical conditions, there was a high degree of variation in the outcomes 
reported across studies69,70, especially arouŶĚ  ‘ƌĞƐŽůƵƚŝŽŶ ? ?  ‘ZĞƐŽůƵƚŝŽŶ ? was often a composite 
outcome71 requiring several criteria to be met. These component criteria can be vague (e.g. 
tolerance of food) and therefore open to gaming and bias72. Variation was also noted in the 
reporting of complications of management, where complications were groups and reported in 
different manners across studies. It is recognised that the variable reporting of outcomes is often 
linked to publication bias73.  
In the 51 included studies, only four included a patient reported outcome measure. The patient 
reported measures were pain, distress and satisfaction, measured on visual analogue scales or 
unvalidated self-rating measures. Whilst these measures should be easy to reproduce, they address 
only one aspect of patient experience and outcome. For example, a patient undergoing an operation 
may have temporarily increased pain but earlier resolution of distention and return of gut function 
than a patient managed conservatively, and these factors may affect their reported outcome in 
different ways28. The fact that an outcome measure is often used does not mean that its 
measurement properties are robust16, assessment of which requires further work, using the 
COnsensus-based Standards for the selection of health status Measurement Instruments (COSMIN) 
assessment tool74. One patient reported outcome measure (PROM) has been developed for patients 
with small bowel obstruction. The population from which it was derived was predominantly one 
with recurrent SBO, and relates to longer term outcomes associated with this. This may limit 
applicability to the general SBO population, despite other positive aspects of this PROM75. This is an 
area which requires further attention, either with the development of a patient reported outcome 
measure for SBO, or through routine use of generic patient outcome measures across multiple 
domains. 
The main limitation of this study is study selection by a single author. Despite this, we believe this 
work is robust; we have followed a predefined protocol, used validated techniques to ensure 
reliability of the search strategy, and manually searched key sources for additional studies. Second 
reviewers were involved in extraction, checking and synthesis of data. 
There are a number of further steps required to generate a core outcome set. These include 
qualitative work with patients to elucidate patient centred outcomes which might not occur to a 
clinician. These outcomes should be added to the long-list identified here, and prioritised by 
stakeholders, using a consensus method such as Delphi. Appropriate measures for the outcomes 
should also be selected, and these measures should be selected for their demonstrated properties of 
reliability and validity. Whilst we cannot propose a definitive core outcome set here, it is likely to 
include: time to resolution/gastrointestinal recovery using a composite measure such as GI-276, 
whether surgical intervention is performed and the time to this event, small bowel resection rates, 
use of critical care facility, duration of hospital stay, and mortality. Specific complications of 
management should be reported including surgical site infection, cardiac complications, respiratory 
complications, renal complications, delirium, and surgical complications including abdominal wall 
dehiscence, enterotomy, and unplanned return to theatre. 
Until a core outcome set is finalised, we would encourage researchers in this field to carefully 
consider the outcomes they report in prospective and trial based research, and ensure that clearly 
defined, reproducible measures are used to facilitate comparison between trials.  
 
Conclusion 
 
There is a high degree of heterogeneity in selection and definition of outcomes in small bowel 
obstruction research. This shows a clear need for consensus between researchers, and the need for 
a core outcome set. Development of a patient reported outcome measure for this condition should 
also be explored. 
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Table Legends 
 
 
 
 
 
 
 
Core 
area 
Domain Outcome reported Frequency 
N (%) 
Pa
th
o
ph
ys
io
lo
gi
ca
l m
an
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st
at
io
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s
 
General 
procedural 
measures 
1. Duration of hospital stay;17,18,20±25,28,30,33±40,42±48,50±52,55±59,63,66,67 
2. Time to resolution;37,40,44±46,48,56±60,63 
3. Time from admission to relief of obstruction50 
36 (71) 
12 (24) 
1 (2) 
Procedure 
specific 
measures 
4. Detection of contrast the colon;38,44,57,59,60,62,63,66,67 
5. Conversion rate from laparoscopic surgery to laparotomy  
(if laparoscopic surgery used);21±23,27,28,33,35,36 
6. Rate of bowel resections;17,25,34,39,45,46,66 
7. NG tube placement duration;18,47,48,55,66 
8. Daily NG tube output;48,55,60,63 
9. Time until abdominal radiographic improvement;42,63 
10. Microbiological measurement of bacterial translocation;18 
11. Mean time for gas canalisation;36 
12. &OLQLFDOHYLGHQFHRIV\VWHPLFLQIODPPDWRU\UHVSRQVH¶DV
measured by recovery of WBC counts, CRP level and ESR;42 
13. Suitability and tolerability of contrast media (based on taste, 
radiologic efficacy and patient reactions);64 
14. Presence of other sutures17 
9 (18) 
8 (16) 
 
7 (14) 
5 (10) 
4 (8) 
2 (4) 
1 (2) 
1 (2) 
1 (2) 
 
1 (2) 
 
1 (2) 
Analgesic 
measures 
15. Time until resolution of pain;36 
16. Time until relief of abdominal pain/distention;42 
17. Abdominal pain since laparoscopic lysis36 
1 (2) 
1 (2) 
1 (2) 
R
es
ou
rc
e 
u
s
e
 
Process 
measures 
18. Operative rate;25,30,37,39±45,50,51,55,57,63,65±67 
19. Non-operative management success rate;25,37±41,43,47,51,58±60,63,66,67 
20. Rate of surgery after failed non-operative management;30,37±
42,45,47,58,60,61,66,67
 
21. Procedure duration;17,18,21,22,27,28,33,36,45,49,51,53 
22. Time from admission to intervention;30,38,39,45±47,56,58,59,66,67 
23. Operative findings;33,47,51,60,66 
24. Intervention success rate;21,22,36,49 
25. Incidence of bowel strangulation;25,45,46 
26. Duration of radiation exposure;49,53 
27. Total number of treatments;58 
28. Admission to the Intensive Care Unit (ICU);30 
29. ICU length of stay;30 
30. Duration of IV therapy45 
18 (35) 
15 (29) 
14 (27) 
 
12 (24) 
11 (22) 
5 (10) 
4 (8) 
3 (6) 
2 (4) 
1 (2) 
1 (2) 
1 (2) 
1 (2) 
Li
fe
 im
pa
ct
 
GI recovery 31. Time until return of bowel function;17,34,35,37,42,52,55,66,67 
32. Time until resumption of a liquid diet;18,33,35,55,60,62,66 
33. Time until resumption of a solid diet;18,35,60 
34. Gastric upset52 
9 (18) 
7 (14) 
3 (6) 
1 (2) 
PRO 35. Pain scores (visual analogue scale and verbal rating scale);55,66 
36. Patient distress (visual analogue scale);49  
37. Patient satisfaction48 
2 (4) 
1 (2) 
1 (2) 
 NG = nasogastric, WBC = White Blood Count, CRP = C-reactive protein, ESR = Erythocyte sedimentation rate, ICU = 
Intensive care unit, IV = intravenous, SBO = Small bowel obstruction 
 
 
 
Table 1: Summary of outcomes reported in OMERACT Framework 
 
 
 
 
 
 
 
 
 
 
CRO 38. Complications of management;17±19,23±25,27±30,33±37,40,41,43,45±
49,52,53,56,57,59,63,65,66
 
39. Mortality;17,19,21±25,27±30,32±36,45±47,51,56,59,63,65 
40. Morbidity;17,19,21±23,25,28,29,31,34,47,51,55 
41. Small bowel transit time;18,64 
42. Drainage volume on first day;42 
43. Intra-abdominal pressure gradient before and after intervention;18 
44. Forced expiratory volume (1 second/forced vital capacity);18 
45. Blood loss17 
31 (61) 
 
24 (47) 
13 (25) 
2 (4) 
1 (2) 
1 (2) 
1 (2) 
1 (2) 
Long term 
outcomes 
46. SBO recurrence rate;17,19,24,26±28,31,32,35,36,41±44,48,51,54,57,60,65,67 
47. Recurrences submitted to surgery/reoperation;17,19,22,29,32,35,36,44,57 
48. Hospital readmission rate;24,34,38 
49. Time to recurrence;24,44,57 
50. Recurrence free survival44,54,57 
21 (41) 
9 (18) 
3 (6) 
3 (6) 
3 (6) 
Study  Term used Definition 
Ambiru. 200854 Resolution rate µ7KHQXPEHU of admissions after which the patient 
left the hospital without undergoing surgery to 
UHVROYHWKHGLVHDVHWRWDOQXPEHURIDGPLVVLRQV¶ 
Burge. 200536 Resolution µ)ODWXVDQGERZHOPRWLRQ¶ 
Choi. 200252 
Choi. 200555 
Rajkumar. 
201459 
Complete 
resolution 
µ(VWDEOLVKHGZKHQWKHV\PSWRPVDQGVLJQVRI
obstruction subsided, and abdominal radiographs 
did not show the small bowel dilateG¶ 
Di Saverio. 
200853 
Resolution µ&RPSOHWHUHVROXWLRQRIFOLQLFDODQGUDGLRORJLFDO
signs and symptoms, with tolerance to a solid 
IRRGGLHW¶ 
Fevang. 200042 Obstruction 
resolved 
µ-XGJHGE\WKHSassage of contrast into the colon 
RUWKHDQDOSDVVDJHRIIODWXVDQGVWRROV¶ 
Gong. 201344 Complete 
resolution 
µ(VWDEOLVKHGZKHQV\PSWRPVDQGVLJQVRI
obstruction subsided, normal flatus and 
defecation returned, and there was no relapse of 
obstructive symptoms after withdrawal of 
VRPDWRVWDWLQ¶ 
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Complication 
Frequency 
(%) 
Wound infection 18,21,23±25,27±29,33,35,46,48,52  13 (25.4) 
Cardiac 23±25,29,30,32,34,35,46 9 (17.6) 
Pneumonia 23,25,28±30,41,43,46,48 9 (17.6) 
Urinary 24,29,30,33±35,43 7 (13.7) 
Bleeding 23,25,28,29,35,65 6 (11.7) 
Respiratory 25,30,32±34,52 6 (11.7) 
Sepsis 19,24,27,29,30,34 6 (11.7) 
Prolonged/postoperative ileus 24,27,29,41,47 5 (9.8) 
Pulmonary 18,23,24,29,35 5 (9.8) 
Thrombosis or embolism 19,24,25,29,46 5 (9.8) 
Anastomotic breakdown 17,30,35,52 4 (7.8) 
Recurrent obstruction 27,28,35,43 4 (7.8) 
Renal 29,30,33,34 4 (7.8) 
Abdominal infection 25,35,46 3 (5.8) 
Enterotomy 27,28 2 (3.9) 
Organ injury/failure 23,32 2 (3.9) 
Peritonitis (unrecognized or secondary perforation) 35,41 2 (3.9) 
Vomiting 19,57 2 (3.9) 
Access injury 28 1 (1.9) 
Bowel resections 57 1 (1.9) 
Bowel strangulation 57 1 (1.9) 
Catheter related infections 48 1 (1.9) 
Cholestasis 48 1 (1.9) 
Coma 29 1 (1.9) 
Dehiscence 29 1 (1.9) 
Delirium 34 1 (1.9) 
Diabetic 24 1 (1.9) 
Failure to wean from ventilator 
 >48 hr 29 
1 (1.9) 
Incisional hernia 28 1 (1.9) 
Intestinal necrosis 24 1 (1.9) 
Intraperitoneal abscess 24 1 (1.9) 
Mental disorders 19 1 (1.9) 
Nerve injury 29 1 (1.9) 
Nostril erosion 43 1 (1.9) 
Paralytic Ileus 33 1 (1.9) 
Patients requiring Percutaneous Transhepatic Cholecystostomy (PTC) 48 1 (1.9) 
Perforation 23 1 (1.9) 
Persistent obstruction 41 1 (1.9) 
Pneumothorax 48 1 (1.9) 
Small bowel leakage 17 1 (1.9) 
Small bowel paralysis 23 1 (1.9) 
Unplanned intubation 29 1 (1.9) 
 
 
Table 3: Complications reported 
 
Figure Legends: 
 
 
 
 
Figure 1: PRISMA Flowchart 
  
Figure 2: Outcomes reported arranged according to the OMERACT frameworks. Circles 
proportionate to frequency of reporting. 
 
 Figure 3: Complications reported grouped by type. Circles proportionate to frequency of reporting. 
 
 
 
 
 
 
 
